Learn About Peripheral T-Cell Lymphoma
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
University Of Virginia Physicians Group
Enrica Marchi is an Oncologist and a Hematologist in Charlottesville, Virginia. Dr. Marchi is rated as an Elite provider by MediFind in the treatment of Peripheral T-Cell Lymphoma. Her top areas of expertise are Peripheral T-Cell Lymphoma, T-Cell Lymphoma, Anaplastic Large Cell Lymphoma, Non-Hodgkin Lymphoma, and Bone Marrow Aspiration. Dr. Marchi is currently accepting new patients.
Memorial Hematology Lymphoma Group
Jasmine Zain is a Hematologist and an Oncologist in New York, New York. Dr. Zain is rated as an Elite provider by MediFind in the treatment of Peripheral T-Cell Lymphoma. Her top areas of expertise are T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Cutaneous T-Cell Lymphoma (CTCL), Bone Marrow Transplant, and Bone Marrow Aspiration.
Jefferson University Physicians
Pierluigi Porcu is an Oncologist and a Hematologist Oncology provider in Philadelphia, Pennsylvania. Dr. Porcu is rated as an Elite provider by MediFind in the treatment of Peripheral T-Cell Lymphoma. His top areas of expertise are T-Cell Lymphoma, Cutaneous T-Cell Lymphoma (CTCL), Mycosis Fungoides, Bone Marrow Transplant, and Bone Marrow Aspiration.
Summary: This phase I trial tests the safety, side effects, and best dose of Q702 in treating patients with hematologic malignancies. Q702 is in a class of medications called immunomodulatory agents. It works by helping the immune system kill cancer cells and by helping the bone marrow to produce normal blood cells. Giving Q702 may be safe, tolerable and/or effective in treating patients with hematologic m...
Summary: This phase I trial studies the best dose and side effects of recombinant vesicular stomatitis virus (VSV) carrying the human (h) sodium iodide symporter (NIS) and Interferon (IFN) beta (β) genes (VSV-hIFNβ-NIS) in combination with ipilimumab and cemiplimab in patients with T-cell lymphoma. A virus, called VSV-hIFNβ-NIS, which has been changed in a certain way, may be able to kill cancer cells with...